Volume 43, Issue 5, Pages (May 2003)

Slides:

Advertisements

Similar presentations

Volume 45, Issue 5, Pages (May 2004)

Advertisements

Medical Management for BPH: The Role of Combination Therapy

Volume 77, Issue 1, Pages (January 2011)

Volume 43, Issue 5, Pages (May 2003)

Volume 68, Issue 3, Pages (September 2015)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 54, Issue 4, Pages (October 2008)

Volume 46, Issue 3, Pages (September 2004)

Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome J. Guinea, M. Torres-Narbona, P.

Let the Games Begin (with EAU Approval)

Meric Sengoz, Ufuk Abacioglu, İlknur Cetin, Levent Turkeri

Prostate Cancer Epidemic in Sight?

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 64, Issue 3, Pages (September 2013)

Helen S. Evans, Henrik Møller European Urology

John P. Mulhall, Francesco Montorsi European Urology

Cholinergic Innervation and Muscarinic Receptors in the Human Prostate

Volume 44, Issue 1, Pages (July 2003)

Volume 46, Issue 4, Pages (October 2004)

Back to the Future: Introduction and Conclusions

Volume 197, Issue 2, Pages S189-S197 (February 2017)

Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) Raymond C. Rosen, Francois Giuliano, Culley.

Volume 51, Issue 1, Pages (January 2007)

Evaluation and Medical Management of Benign Prostatic Hyperplasia

Alexandre de la Taille European Urology Supplements

Pseudohyperplastic Adenocarcinoma of the Prostate

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 54, Issue 5, Pages (November 2008)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 60, Issue 4, Pages (October 2011)

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Volume 61, Issue 3, Pages (March 2012)

Counselling the Prostate Cancer Patient

Prostate Cancer Epidemic in Sight?

Volume 71, Issue 4, Pages (April 2017)

Volume 64, Issue 4, Pages (October 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Milen Pavlović, Nebojša Jović, Tatjana Pekmezović

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Richard C. Harkaway European Urology Supplements

Volume 54, Issue 2, Pages (August 2008)

Volume 46, Issue 6, Pages (December 2004)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Tim Schneider European Urology Supplements

Volume 71, Issue 5, Pages (May 2017)

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

How and When to Take Prostate Biopsies

HIFU: Local Treatment of Prostate Cancer

What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice? François Desgrandchamps European Urology.

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Martin Michel, Jean de la Rosette European Urology Supplements

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Paiva J.A. , Pereira J.M. Clinical Microbiology and Infection

The Benefits of Dual Inhibition of 5α Reductase

Manfred Wirth, Peter Iversen, David McLeod, William See

Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Epidemiology and Demographics of Prostatitis

Days at Home after Surgery: An Integrated and Efficient Outcome Measure for Clinical Trials and Quality Assurance Max Bell, Lars I. Eriksson, Tobias.

Neal S Goldstein, MD The Annals of Thoracic Surgery

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Introduction European Urology Supplements

Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette

Presentation transcript:

Volume 43, Issue 5, Pages 528-534 (May 2003) Drug Treatment of Benign Prostatic Hyperplasia and Hospital Admission for BPH- Related Surgery P.C Souverein, J.A Erkens, J.J.M.C.H de la Rosette, H.G.M Leufkens, R.M.C Herings European Urology Volume 43, Issue 5, Pages 528-534 (May 2003) DOI: 10.1016/S0302-2838(03)00089-7

Fig. 1 BPH drug use and prostatic surgery in the PHARMO area 1991–2000 (source: PHARMO Institute for Drug Outcomes Research). European Urology 2003 43, 528-534DOI: (10.1016/S0302-2838(03)00089-7)

Fig. 2 Kaplan–Meier survival plot for patients using 5-alpha-reductase inhibitors and patients using alpha-blockers. European Urology 2003 43, 528-534DOI: (10.1016/S0302-2838(03)00089-7)